The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 03, 2021
Filed:
Jan. 03, 2020
Applicant:
Immunomedics, Inc., Morris Plains, NJ (US);
Inventors:
Serengulam V. Govindan, Summit, NJ (US);
Sung-Ju Moon, New Providence, NJ (US);
David M. Goldenberg, Delray Beach, FL (US);
Assignee:
Immunomedics, Inc., Morris Plains, NJ (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 47/68 (2017.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07D 491/22 (2006.01); A61K 31/4745 (2006.01); C07K 16/18 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6803 (2017.08); A61K 31/4745 (2013.01); A61K 45/06 (2013.01); A61K 47/6841 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6853 (2017.08); A61K 47/6855 (2017.08); A61K 47/6857 (2017.08); A61K 47/6861 (2017.08); A61K 47/6889 (2017.08); A61N 5/10 (2013.01); C07D 491/22 (2013.01); C07K 16/1063 (2013.01); C07K 16/18 (2013.01); C07K 16/2803 (2013.01); C07K 16/2833 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3046 (2013.01); C07K 16/3076 (2013.01); C07K 16/3092 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/40 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01); C07K 2317/94 (2013.01); Y02A 50/30 (2018.01);
Abstract
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.